Clinical Trials Logo
  1. Home
  2. Gaucher's Disease
  3. NCT06188325

A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers

Gaucher's Disease Clinical Trial

Official title:
A Randomized, Three-Period Crossover Study of Single and Repeated Doses for Three Different Strengths of Eliglustat in Healthy Adult, CYP2D6 Extensive and Poor Metabolizers

Clinical Trial Summary

The primary objective of the study is to evaluate dose proportionality and pharmacokinetics for three different dose levels of eliglustat after single and repeated administration.

Clinical Trial Description

Duration of the study for each subject will be between 42 to 79 days, including a screening period up to 28 days, 3 treatment periods of 7 days each period, a washup period of 7-10 days, and an end-of-study visit 8+/-2 days after the last administration. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06188325
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 1
Start date January 1, 2018
Completion date March 26, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT00001289 - Effects of Enzyme Replacement in Gaucher's Disease N/A
Completed NCT00004488 - Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease Phase 2
Completed NCT00001410 - PEG-Glucocerebrosidase for the Treatment of Gaucher Disease Phase 1
Recruiting NCT00004293 - Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease Phase 2
Completed NCT00004294 - Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease Phase 1
Completed NCT04656600 - Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ Phase 4
Completed NCT01427517 - Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease Phase 1
Completed NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism Phase 2/Phase 3
Completed NCT00001234 - Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells Phase 1
Completed NCT00001416 - Bone Response to Enzyme Replacement in Gaucher's Disease Phase 2
Completed NCT06193304 - A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth Phase 1
Active, not recruiting NCT00005900 - Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT01586455 - Human Placental-Derived Stem Cell Transplantation Phase 1